The effect of single dose albendazole (400 mg) treatment on the human gut microbiome of hookworm-infected Ghanaian individuals.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 07 2023
12 07 2023
Historique:
received:
27
12
2022
accepted:
07
07
2023
medline:
14
7
2023
pubmed:
13
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
Microbes play a key role in human gut homeostasis, metabolic, immunologic and physiopathology of the body. A longitudinal study conducted during 2018-2021 in the Kintampo North Municipality in Ghana demonstrated low hookworm infection cure rates following treatment with a single dose of 400 mg albendazole in some communities. To investigate associations between hookworm infection and the gut microbiome, we examined stool samples from consented participants who were either cured or remained infected after treatment. At each time point, stool was collected prior to and 10-14 days after albendazole treatment. We used 16S rRNA amplicon sequencing of DNA extracted from stool samples to investigate the composition and diversity of the gut microbiota and to identify potential microbial biomarkers associated with treatment outcomes. Hookworm infection was associated with increased species richness (p = 0.0093). Among treated individuals, there was also a significant variation in microbiota composition at 10-14 days following single-dose albendazole treatment. Individuals cured of hookworm infection after treatment showed a significant reduction in microbiota composition when compared to their pre-treatment state (ANOSIM; p = 0.02), whilst individuals who failed to clear the infection showed no change in microbiota composition (ANOSIM; p = 0.35). Uninfected individuals and those who were successfully treated were similar in their microbial composition and structure. We also found that the abundance of Clostridia spp. was increased in infected individuals pre- or post-treatment. Predictive functional profiling revealed the enrichment of two pyruvate ferredoxin oxidoreductase subunit pathways in individuals who remained infected after treatment (p < 0.05), alluding to an upturn of strictly anaerobic commensal bacteria such as Clostridia spp. This study suggests a relationship between human gut microbiome dysbiosis and albendazole therapy outcomes of hookworm infection. Future studies will further characterize specific biomarkers identified within this study to establish their potential for assessment of pharmacological responses to anthelminthic therapies, as well as explore the possibility of using probiotic supplementation as an adjunct treatment to increase albendazole effectiveness against hookworm.
Identifiants
pubmed: 37438457
doi: 10.1038/s41598-023-38376-3
pii: 10.1038/s41598-023-38376-3
pmc: PMC10338455
doi:
Substances chimiques
Albendazole
F4216019LN
RNA, Ribosomal, 16S
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
11302Subventions
Organisme : NIAID NIH HHS
ID : R01 AI132452
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI129916
Pays : United States
Organisme : NIH HHS
ID : U19AI129916
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Br J Nutr. 2019 Jul 28;122(2):131-140
pubmed: 30924428
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Am J Trop Med Hyg. 2011 May;84(5):792-800
pubmed: 21540391
Front Microbiol. 2017 Oct 13;8:1979
pubmed: 29081768
PeerJ. 2019 Jan 7;7:e6200
pubmed: 30643702
Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):372-378
pubmed: 30007544
Protein Cell. 2010 Aug;1(8):718-25
pubmed: 21203913
Parasitology. 2000;121 Suppl:S113-32
pubmed: 11386684
JAMA. 2008 Apr 23;299(16):1937-48
pubmed: 18430913
Acta Trop. 2020 Jan;201:105214
pubmed: 31600519
Sci Rep. 2018 Nov 5;8(1):16321
pubmed: 30397210
Front Cell Infect Microbiol. 2017 Apr 27;7:144
pubmed: 28497029
Front Cell Infect Microbiol. 2021 Oct 01;11:678522
pubmed: 34660333
mBio. 2021 Dec 21;12(6):e0289021
pubmed: 34933444
Parasitol Int. 2020 Apr;75:102051
pubmed: 31911156
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Genome Biol. 2020 May 25;21(1):122
pubmed: 32450885
Bioinformatics. 2014 Nov 1;30(21):3123-4
pubmed: 25061070
Sci Rep. 2018 Jul 25;8(1):11192
pubmed: 30046129
BMC Microbiol. 2020 Sep 14;20(1):283
pubmed: 32928123
Clin Infect Dis. 2021 Jul 15;73(2):e494-e502
pubmed: 32668456
Microbiome. 2016 Oct 21;4(1):57
pubmed: 27769291
Am J Trop Med Hyg. 2017 Feb 8;96(2):347-354
pubmed: 27895280
Nat Biotechnol. 2020 Jun;38(6):685-688
pubmed: 32483366
Nat Commun. 2022 Feb 25;13(1):1063
pubmed: 35217670
FEBS Open Bio. 2021 May;11(5):1332-1342
pubmed: 33660937
Front Cell Infect Microbiol. 2021 Mar 17;11:625913
pubmed: 33816335
PLoS Pathog. 2019 Dec 16;15(12):e1008066
pubmed: 31841569
Microbiome. 2018 Dec 17;6(1):226
pubmed: 30558668
Cureus. 2022 Aug 2;14(8):e27624
pubmed: 36072190
mBio. 2019 Apr 23;10(2):
pubmed: 31015324
Nat Protoc. 2021 Jan;16(1):458-471
pubmed: 33277629
Sci Rep. 2019 Jul 31;9(1):11121
pubmed: 31366962
Mol Cell Probes. 1998 Apr;12(2):71-8
pubmed: 9633041
Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):262-271
pubmed: 28697451
Gut. 2018 Sep;67(9):1716-1725
pubmed: 29934437
PLoS Negl Trop Dis. 2011 Jun;5(6):e1200
pubmed: 21666800
J Clin Gastroenterol. 2011 Nov;45 Suppl:S154-8
pubmed: 21992956
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
PLoS Negl Trop Dis. 2018 Aug 9;12(8):e0006620
pubmed: 30091979
Biochem Biophys Res Commun. 2021 Oct 1;572:151-156
pubmed: 34364295
Curr Opin Gastroenterol. 2018 Jan;34(1):3-10
pubmed: 29189354
Gut Microbes. 2016 Sep 2;7(5):428-34
pubmed: 27494088
Gut Pathog. 2013 Aug 13;5(1):23
pubmed: 23941657
Parasite Immunol. 2016 Jan;38(1):5-11
pubmed: 26345715
Microbiome. 2016 Jan 12;4:2
pubmed: 26757703
Southeast Asian J Trop Med Public Health. 1997 Sep;28(3):563-9
pubmed: 9561609
PLoS Negl Trop Dis. 2014 May 22;8(5):e2880
pubmed: 24851867
Nat Biotechnol. 2019 Aug;37(8):852-857
pubmed: 31341288
PLoS One. 2016 Sep 19;11(9):e0163148
pubmed: 27643503